- Membership Level
- Company Headquarters
- 123 Saginaw Drive Redwood City, CA 94063
- Contact Name
At Heron, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents. Our goal is to build on therapeutics with well-known pharmacology by improving their safety and efficacy as well as broadening their potential field of use.
We are currently developing the following pharmaceutical products:
- SUSTOL® (granisetron) Injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). A New Drug Application (NDA) for SUSTOL is currently under review by the U.S. Food and Drug Administration (FDA).
- HTX-019, also being developed for the prevention of CINV, has the potential to become the first polysorbate 80-free, intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist. We intend to file an NDA for HTX-019 using the 505(b)(2) regulatory pathway in the second half of 2016.
- HTX-011 is our long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of post-operative pain. In a Phase 2 study in patients undergoing bunionectomy, HTX-011 demonstrated robust reductions in pain intensity compared to placebo. HTX-011 is currently being evaluated in a broad-based development program.
All of our product candidates utilize our innovative science and technology platforms, including our proprietary Biochronomer® drug delivery technology, which can deliver therapeutic levels of a wide range of otherwise short-acting pharmacological agents over a period of days to weeks with a single injection.